London Daily

Focus on the big picture.
Thursday, Jul 31, 2025

US officials may need 2 weeks or more to determine if Johnson & Johnson's vaccine causes rare blood clots

US officials may need 2 weeks or more to determine if Johnson & Johnson's vaccine causes rare blood clots

The CDC still might not have enough data to evaluate a blood clot link by its Friday meeting, two senior health officials told Politico.

US federal agencies may need two weeks or more to know whether Johnson & Johnson's coronavirus vaccine is linked to rare blood clots, two senior White House health officials told Politico on Saturday.

US regulators recommended a pause in the distribution of J&J's shot last Tuesday due to six reports of clotting among women who'd recently received the vaccine.

The particular blood clot in question, central venous sinus thrombosis (CVST), forms in the brain — so it can lead to headaches or stroke. In an average year, the condition occurs in about five people out of every million.

The Centers for Disease Control and Prevention's vaccine advisory panel is scheduled to convene Friday to discuss whether to lift the vaccine pause. But two health officials told Politico that the CDC still might not have enough data by then to determine if J&J's vaccine indeed causes rare clots.

US regulators may ultimately consider placing age- or gender-based restrictions on the shot, which has been authorized for people ages 18 and older. Alternatively, regulators could simply deliver stronger warnings about possible blood clots in unusual cases.

Many political leaders and medical experts worry that if regulators take too long to evaluate the potential blood clot link, an increasing share of Americans will lose trust in J&J's vaccine.

"The longer the pause is, the longer it's going to take for us to convince people that this particular vaccine is safe again," Arkansas Gov. Asa Hutchinson told Politico.

Peter Gulick, an associate professor of medicine at Michigan State University, said the J&J pause could delay the prospect of herd immunity — the threshold beyond which the virus won't be able to pass easily from person to person.

"The fear is that, hearing all this, the anti-vaxxers and even the ones on the fence are falling off the fence now into the arena of 'I don't think I want to get any vaccine until things are known a little more,'" Gulick told Insider. "We may have taken two steps backwards as far as our wanting to get herd immunity."

Searching for blood clots in a 'muddied water' of data


Johnson & Johnson's coronavirus vaccine is delivered as a single shot, while both Pfizer's and Moderna's require two jabs.


The CDC's vaccine advisory panel has already met once to review the rare blood clot cases. At a meeting last Wednesday, the panel recommended continuing the pause on J&J's vaccine until more data could be gathered.

"It's important from the perspective of the public: When we say rare, what does that mean?" Dr. Beth Bell, a professor of global health at the University of Washington, said during the meeting. "I want to be able to feel comfortable with my family members and myself getting this vaccine."

US regulators are now encouraging doctors to report any post-vaccination CVST cases over the last few weeks. Regulators are also working with Johnson & Johnson to find out more about the six reported cases — in particular, whether the women had underlying health problems or were taking any medications that could have predisposed them to clotting.

So far, regulators have noticed a few patterns: The women were between the ages of 18 and 48. They also had a rare combination of CVST and low levels of platelets — colorless blood cells that help clots form.

Before the vaccines were authorized, this combination was primarily seen in association with the blood-thinning drug heparin. In rare cases, people taking the medication develop antibodies that bind to a specific platelet, which can make them more susceptible to clots.

"This observation of the low platelet count is part of the mystery and something that has to be worked through to see if that's connected or not," Namandjé Bumpus, director of the pharmacology and molecular sciences department at Johns Hopkins Medicine, told Insider.

But medical experts stressed the need for more data before associating the clots with any particular group yet.

"Everything is just like a big muddied water and then you just try to clear things out as much as you can to try to evaluate what is going on," Gulick said.

Vaccinations may slow for the homeless, prisoners, or rural Americans


Yvonne Gibbs, 72, receives Moderna's COVID-19 vaccine, at the TCF Center in Detroit.


Shortly after US regulators announced a pause in J&J's vaccine, White House COVID-19 coordinator Jeff Zients said the recommendation wouldn't affect the pace of the US vaccine rollout.

"We have more than enough supply of Pfizer and Moderna vaccines to continue the current pace of about 3 million shots per day," Zients said at a Tuesday press briefing.

Indeed, many health departments, pharmacies, and vaccine clinics that planned on administering Johnson & Johnson were able to quickly procure other shots so people didn't lose their appointments.

But some vaccination sites — particularly those in rural areas — were forced to shut down temporarily. A state-run mass vaccination site in Aurora, Illinois, was canceled earlier this week, terminating appointments of 1,000 people. Around the same time, a Johnson & Johnson clinic in Jefferson County, Illinois, put vaccinations on hold.

The J&J pause has also slowed the pace of vaccinations for homeless people, prisoners, and those unable to leave their homes due to illness or old age. J&J's vaccine is the only single-dose shot authorized in the US, so it's the easiest to administer. It's also easier to store than the Pfizer or Moderna vaccines (it can be kept in standard refrigerators rather than freezers).

On top of that, people may gravitate toward J&J's vaccine if they're afraid of needles or have difficulty taking time off work to get vaccinated.

"We're actually seeing that some people opt for the Johnson and Johnson shot just because of their circumstances — it's one dose, it's available, and so on," Johan Bester, director of bioethics at the University of Nevada, Las Vegas School of Medicine, told Insider.

Without the J&J option, medical experts said, US health officials may have a harder time convincing more Americans to get vaccinated — even as new, more contagious variants drive up cases across the country.

Newsletter

Related Articles

0:00
0:00
Close
Former Judge Charged After Drunk Driving Crash Kills Comedian in Brazil
Jeff Bezos hasn’t paid a dollar in taxes for decades. He makes billions and pays $0 in taxes, LEGALLY
China Increases Use of Exit Bans Amid Rising U.S. Tensions
IMF Upgrades Global Growth Forecast as Weaker Dollar Supports Outlook
Procter & Gamble to Raise U.S. Prices to Offset One‑Billion‑Dollar Tariff Cost
House Republicans Move to Defund OECD Over Global Tax Dispute
Botswana Seeks Controlling Stake in De Beers as Anglo American Prepares Exit
Trump Administration Proposes Repeal of Obama‑Era Endangerment Finding, Dismantling Regulatory Basis for CO₂ Emissions Limits
France Opens Criminal Investigation into X Over Algorithm Manipulation Allegations
A family has been arrested in the UK for displaying the British flag
Mel Gibson refuses to work with Robert De Niro, saying, "Keep that woke clown away from me."
Trump Steamrolls EU in Landmark Trade Win: US–EU Trade Deal Imposes 15% Tariff on European Imports
ChatGPT CEO Sam Altman says people share personal info with ChatGPT but don’t know chats can be used as court evidence in legal cases.
The British propaganda channel BBC News lies again.
Deputy attorney general's second day of meeting with Ghislaine Maxwell has concluded
Controversial March in Switzerland Features Men Dressed in Nazi Uniforms
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
Thai Civilian Death Toll Rises to 12 in Cambodian Cross-Border Attacks
TSUNAMI: Trump Just Crossed the Rubicon—And There’s No Turning Back
Over 120 Criminal Cases Dismissed in Boston Amid Public Defender Shortage
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
Trump Announces $550 Billion Japanese Investment and New Trade Agreements with Indonesia and the Philippines
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
×